Clinical Report: Can Statin Muscle Risk Be Predicted?

Overview

This study developed and validated a clinical model to predict the risk of serious muscle disorders in patients eligible for statin treatment. The model demonstrated good performance in predicting 1-, 5-, and 10-year risks using data from nearly 5.7 million patients, derived from linked electronic health record data in England's Clinical Practice Research Datalink.

Background

Statins are widely prescribed for cardiovascular disease prevention, but muscle-related side effects can limit their use. Understanding the individualized risk of serious muscle disorders is crucial for optimizing statin therapy. This study addresses the need for predictive tools that can aid in clinical decision-making regarding statin treatment.

Data Highlights

Key Findings

• The final model included 22 predictors, with previous muscle disorders being the strongest predictor.
• Adjusted 10-year cumulative incidences of serious muscle disorders were 0.45% in the derivation cohort and 0.44% in the validation cohort.
• The model achieved C-index values of 0.84, 0.81, and 0.78 for 1-, 5-, and 10-year predictions, respectively, indicating good predictive performance.
• 99.6% of patients in the validation cohort had a predicted 10-year risk below 10%.
• Among patients with a QRISK2 score above 10%, 62.5% were not receiving statins.

Clinical Implications

The developed model can assist clinicians in identifying patients at higher risk for serious muscle disorders when considering statin therapy.

Conclusion

The study presents a validated model for predicting serious muscle disorder risk in statin-eligible patients, which could complement existing cardiovascular risk assessment tools. Further validation in diverse populations is necessary.

Related Resources & Content

1. Cai T., et al., The Lancet Digital Health, 2023 -- Can Statin Muscle Risk Be Predicted?
2. Clinical Research in Cardiology — Individualized Assessment of Statin Benefits for Primary and Secondary Vascular Disease Prevention in Older Adults
3. Clinical Rheumatology (Springer) — Increasing recognition of statin-associated anti-HMGCR antibody–positive autoimmune myopathy: a single-center retrospective study
4. MDSpire News — Statins and Survival After 80
5. Journal of General Internal Medicine — Reframing Statin Prescribing for Low-Risk Patients: A Two-Visit Approach
6. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia
7. NOCEBO AND PLACEBO–DRIVEN STATIN SIDE EFFECTS: CLOSING THE GAP BETWEEN TRIALS AND REAL–WORLD CARE
8. Predicting the risk of serious muscle disorders in individuals eligible for statin treatment in England: derivation and validation of a clinical prediction model - PubMed